Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For R
Insight Molecular Diagnostics Inc., (NASDAQ: IMDX ), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring. The event will provide an overview of GraftAssure, currently under review by the FDA to be commercialized in kitted form for labs to test patients for kidney transplant rejection. Dr. Liebo will discuss how a kitted GraftAssure test (GraftAssureDx) can be used for in-house heart transplant rejection monitoring, as well as implications for the industry and patients.
Insight Molecular Diagnostics Inc., (NASDAQ: IMDX ), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring.
The event will provide an overview of GraftAssure, currently under review by the FDA to be commercialized in kitted form for labs to test patients for kidney transplant rejection.
Dr.
Liebo will discuss how a kitted GraftAssure test (GraftAssureDx) can be used for in-house heart transplant rejection monitoring, as well as implications for the industry and patients.